Silymarin: meta-analysis of COVID-19 studies

All studies Hospitalization RCTs Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−20%

Hospitalization (1)8%

RCTs (1)−20%

Late (1)−20%

00.511.5+

← Silymarin
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

October 2026

Silymarin COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Aryan (DB RCT)−20%1.20 · 0.36–4.02oxygen time25 (n)25 (n)

Late treatment−20%1.20 · 0.36–4.0225 (n)25 (n)20% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.78

All studies−20%1.20 · 0.36–4.0225 (n)25 (n)20% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7800.511.52+

Rotate screen for more detailsIncrease width for more details

← Silymarin
reduces riskSilymarin
increases risk →

October 2026

Silymarin COVID-19 hospitalization results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Aryan (DB RCT)8%0.92 · 0.73–1.16hosp. time25 (n)25 (n)

Late treatment8%0.92 · 0.73–1.1625 (n)25 (n)8% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.5

All studies8%0.92 · 0.73–1.1625 (n)25 (n)8% lower risk

Tau² = 0.00, I² = 0.0%, p = 0.500.511.52+

Rotate screen for more detailsIncrease width for more details

← Silymarin
reduces riskSilymarin
increases risk →

October 2026

Silymarin COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Aryan (DB RCT)−20%1.20 · 0.36–4.02oxygen time25 (n)25 (n)

Late treatment−20%1.20 · 0.36–4.0225 (n)25 (n)20% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.78

All studies−20%1.20 · 0.36–4.0225 (n)25 (n)20% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7800.511.52+

Rotate screen for more detailsIncrease width for more details

← Silymarin
reduces riskSilymarin
increases risk →

October 2026

Silymarin COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Aryan (DB RCT)−20%1.20 · 0.36–4.02oxygen time25 (n)25 (n)

Late treatment−20%1.20 · 0.36–4.0225 (n)25 (n)20% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.78

All studies−20%1.20 · 0.36–4.0225 (n)25 (n)20% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7800.511.52+

Rotate screen for more detailsIncrease width for more details

← Silymarin
reduces riskSilymarin
increases risk →

October 2026

Silymarin COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Aryan (DB RCT)−20%1.20 · 0.36–4.02oxygen time25 (n)25 (n) Aryan (DB RCT)−9%1.09 · 0.91–1.30oxygen time25 (n)25 (n) Aryan (DB RCT)8%0.92 · 0.73–1.16hosp. time25 (n)25 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Silymarin
reduces riskSilymarin
increases risk →